Edouard Cukierman, Chairman – Cukierman & Co. Investment House
Mr. Edouard Cukierman is the Founder and Managing Partner of Catalyst Investments and serves as the Chairman of Cukierman & Co. Investment House. Since its establishment in 1993, Cukierman & Co. Investment House has been engaged in more than € 5.5 billion cross-border transactions across industries. Catalyst was the only Israeli venture fund that invested in Mobileye.
Prior to establishing and managing Catalyst Investments in 2000, Mr. Cukierman was the President and CEO of Astra Technological Investments, a Venture Capital Fund established in 1993, which was the first Israeli company to go public in Continental Europe.
Today, Edouard Cukierman serves as board member of Tufin technologies, the leading private Cyber security company in Israel, and Dori Media Group in Israel. Edouard Cukierman is the Founder of the GoforIsrael annual conference.
Mr. Cukierman is a board member of "Alliance Israelite Universelle en Israel" and a board member of Sar-El (Association that brings volunteers from across the world to the IDF in Israel). He is also a director of the Asia M&A Association in China.
Edouard Cukierman together with Dr. Daniel Rouach co-authored the book “Israel Valley Le bouclier technologique de l’innovation” published in June 2013 by Edition Pearson in Paris, translated into Chinese in November 2014, and in Italian in June 2016
Mr. Cukierman served for many years as a reserve officer in the Crisis & Hostage Negotiation team and in the Spokesperson’s Unit of the IDF.
Mr. Cukierman holds an MBA from INSEAD, France and a B.Sc. from the Technion – Israel’s Institute of Technology.
Dr. Laurent Choppe, Managing Partner – Cukierman & Co. Life Sciences
Laurent Choppe has lead Cukierman & Co. Life Sciences since 2008 and has been involved in more than 60 medtech and biotech corporate finance transactions and advisory assignments for the Cukierman group. His team works worldwide with venture- backed and middle market companies for fundraising, licensing deals and M&A transactions, as well as strategic projects for key life sciences industry players.
Dr. Choppe is a board member of Israel Brain Technology (IBT) - a non-profit organization whose mission is to accelerate the commercialization of Israel’s brain-related innovation and establish Israel as a leading international brain technology hub.
After a veterinary practice and a new venture management experience, he worked 10 years in Schering-Plough (today Merck & Co.) in marketing positions in dermatology, allergy, respiratory and animal health in France, served as General Manager in Israel and Vice President of Virology, Oncology and Cardiology in Canada. He then served 4 years as International General Manager at Bellus Health (ex-Neurochem, NASDAQ & TSE, dedicated to Alzheimer’s disease and AA amyloidosis).
Dr. Choppe is a Doctor of Veterinary Medicine of the University Paris XII, laureate of the École Nationale Vétérinaire d'Alfort, CES of Veterinary Ophthalmology and earned a MBA from INSEAD (Fontainebleau, France). He is married, father of 3 and lives in Lausanne (Switzerland).
Yair Shiran, Minister of Commercial Affairs and Deputy Permanent Representative of Israel to the WTO - Geneva, Switzerland
Yair Shiran joined the Government of Israel in 1992. Since then, he has been serving in senior diplomatic and executive positions in Israel and Abroad. Mr. Shiran assumed his responsibilities as Minister-Commercial Affairs and Deputy Permanent Representative of Israel to the World Trade Organization, in Geneva/Switzerland in August 2018.
Prior to that, Mr. Shiran served as the Head of the Industry Administration in the Ministry of Economic Affairs. In that position, he was responsible for shaping industrial policy and regulations, aiming to support Industrial development throughout the country, and particularly, in the periphery. In parallel, he served as the Chairman of the TRQ Committee that was charged with the task of introducing reforms in the Israeli food market, so as to enhance competition and reduce the prices of basic food products to the consumers.
From 2006 to 2011, Mr. Shiran served as Israel's Economic Minister to North America. Based in New York City, he was responsible for the Government’s effort to promote bilateral trade and to strengthen economic collaboration between Israel and the United States.
Between 2002 and 2006, Mr. Shiran served as the Director of International Agreements and Trade Policy at the Ministry of Industry, Trade and Labor. In this position, Mr. Shiran served as the Chief Trade Negotiator for international trade agreements with Israel’s key trading partners, including the U.S., Canada, Egypt, Turkey, as well as other European and Asian countries. During this, term Mr. Shiran headed the Israeli delegation to the trilateral trade negotiations that led to the signing of the historic US-Egypt-Israel QIZ agreement. This agreement resulted in an immediate increase of 250% in the volume of bilateral trade between Israel and Egypt.
Between 1996-2001, Mr. Shiran served in the Mission of Israel to the World Trade Organization (WTO) in Geneva. During his first term in Geneva, he was elected to Chair the WTO committees on Information Technology and Market Access.
For the past decade Mr. Shiran has also been lecturing as an Adjunct Professor at a number of Business Schools, including The Hebrew University of Jerusalem, The Arison School of Business at the Interdisciplinary Centre (IDC), Herzliya and at Fox Business School at Temple University in Philadelphia. Mr. Shiran received his Masters of Arts in Public Administration from the Kennedy School of Government at Harvard University, where he studied as a Wexner Fellow. He also holds a Masters of Arts degree in Business Administration and a Bachelors of Arts degree in Economics and Political Science from the Hebrew University of Jerusalem. Mr. Shiran is also a graduate of the Israeli Academy of National Security.
Dr. Ami Appelbaum, Chief Scientist - Ministry of Economy and Industry & Chairman - Israel Innovation Authority
Dr. Ami Appelbaum is the Chief Scientist and the Chairman of the Board of Israel Innovation Authority (IIA). Dr. Appelbaum has more than 36 years’ experience in research, development and senior level management in the field of the Semiconductor.
Prior to the current job as Chief Scientist, Dr. Appelbaum served for 22 years at numerous executive positions at KLA Tencor, $15.6B Market Cap and world leader in the business of capital equipment for the semiconductor industry based in the Silicon Valley, CA. Dr. Ami Appelbaum recent job was Corporate Senior Vice President and president of KLA Tencor Israel.
Dr. Appelbaum also held jobs as General Manager of a startup by the name Gallium Arsenide Diodes (GAD), in Israel. VP Operations and Program Manager at Semiconductor Devices (SCD) in Israel, manager of semiconductor lasers and detector development at Rockwell International in Richardson Texas and Newbury Park California and Member of Technical Staff (MTS) at AT&T Bell Lab in Murray Hill New Jersey (US).
Dr. Appelbaum received his Doctorate and Master degrees from the Technion, Israel Institute of Technology in Haifa in the years 1983 and 1980, respectively and his Engineering degree from Ben Gurion University in Beer Sheba in 1977 , all in the field of materials engineering. Dr. Appelbaum is the author and co-author of more than 50 scientific and technical publications, and holds 7 patents in the field of semiconductor equipment and processing.
Marius Nacht, Anchor Investor – aMoon Fund
Marius Nacht is the anchor investor L.P. at aMoon. In 1993, Marius co-founded Check Point Software Technologies Ltd. (NASDAQ: CHKP), a global pioneer of cybersecurity and the second largest company in Israel in terms of market capitalization. He is currently the Chairman of Check Point and considered one of the founding fathers of the global cybersecurity industry.Marius recently co-founded the 8400 Health Network, an NGO fostering cross-sector collaboration to position Israel as a global life sciences leader.Marius holds a BSc, cum laude, in Physics and Mathematics, from Hebrew University, and an MSc in Electrical Engineering and Communications Systems from Tel Aviv University. He is a graduate of the IDF elite Talpiot technological academy.
Daniel Cohen, Partner – Cukierman & Co. Life Sciences
Involved with Cukierman Life Sciences since 2008, Daniel has 18 years of experience in Healthcare sector in various positions (Investment Banking, Venture Capital, Fund of Funds, Business Development & Consulting).
Daniel is the CEO & Founder of Sollal Partners, a consulting firm offering management & due diligence services to leading funds in Israel, Europe and China and serves on the board of several Life Science companies.
Prior to Sollal, Daniel managed Fosun Pharma's activity in Israel leading major investments and strategic operations (e.g. Kite Pharma, Tyto Care, Pontifax, Tapingo...), served as Principal at Credit Agricole Private Equity Israel and Director at Market Bridges.
Dr. Yair Schindel, Co-Founder & Managing Partner - aMoon Fund
Previously, Yair served as the founding CEO of the State of Israel’s National Digital Bureau, responsible for digitizing governmental services and stimulating economic growth.
Yair is the founder of the MAOZ Network, an NGO building collaboration between Israel’s most influential leaders, with over 300 alumni dedicated to building collaboration between the private, social and public sectors.
Yair was an executive, investor, board or advisory board member in several healthcare startups including OmniGuide, Zebra Medical Vision, and Medisafe. Yair earned his BSc and MD degrees at Ben-Gurion University and his MBA at Harvard Business School. He served in the IDF for five years and graduated as Chief Medical Officer for the Israeli Navy Seals, known as “Shayetet 13”
Dr. Pini Orbach, Head of Pharma – Arkin Holdings
Dr. Pini Orbach joined Arkin Holdings in 2010 as Head of its Pharma Division. Dr. Orbach is a member of the board in several of its pharmaceutical companies, including UroGen Pharma and Quiet Therapeutics, from which he shares his extensive hands-on drug development and business experience. He originally gained his foundation in US based companies such as, Arisaph Pharmaceuticals and Epix Pharmaceuticals (NASDAQ, EPIX), as well as Israeli-based companies such as, cCAM BioTherapeutics - a cancer immunotherapy company, which was sold to Merck in 2015 for $605M. He holds a Ph.D. from the Department of Physiology and Functional Genomics, University of Florida, and was a postdoctoral fellow at the Cardiovascular Research Center, Harvard Medical School - Massachusetts General Hospital.
Yair Geva, Partner & Head of Hi-Tech – Herzog Fox & Neeman Law Office
Yair Geva heads Herzog's Hi-Tech Group and is a member of the Firm’s Executive Committee. Yair is a corporate transactional lawyer whose practice includes extensive representation in mergers and acquisitions, private equity and venture capital investments,and general corporate counseling. He is ranked among the top mergers and acquisitions and hi-tech lawyers in Israel by IFLR1000. Yair led some of the most notable recent transactions in Israel, among other matters he represented PepsiCo in its $3.2 billion acquisition of Soda Stream, Sygnia in its $250 million sale to Temasek, Tapingo in its $150 million sale to GrubHub and United Therapeutics in its $250 million acquisition of SteadyMed. Yair also led EnteraBio’s recent IPO on Nasdaq. He represents many of the most prominent early stage startups and growth companies in Israel in a range of industries including e-commerce, cyber, fintech, blockchain, property and real estate tech, biotech and digital health. He works closely with entrepreneurs, CEOs and Boards of Directors on transactions, investments and other strategic matters. Prior to joining Herzog, Yair practiced at the M&A groups of Gibson Dunn and David Polk in New York. Yair received his LLM. from NYU school of Law and his LLB from the Tel Aviv University, both magna cum laude. He's a member of the New York and Israeli Bars.
Dr. David Sidransky, Co-Founder & Managing Partner - Israel Biotech Fund
Dr. Sidransky is a renowned oncologist, research scientist and Professor of Oncology and Cellular & Molecular Medicine at John Hopkins University and Hospital. Dr. Sidransky was Vice Chairman of ImClone Systems until its acquisition by Eli Lilly for $6.5B in 2008. He founded several biotechnology companies, including Oncormed Pharmaceuticals, (NASDAQ: OMED), a genetic testing company that was sold to Gene Logic in 1998, and Response Genetics (NASDAQ: RGDX), a developer of markers for cancer therapy.
Efi Cohen-Arazi, Founder & CEO – Rainbow Medical
Mr. Efi Cohen Arazi, CEO and Co-Founder of Rainbow Medical, Israel’s leading medical device innovation house focused on inventing and developing game changing solutions for sizeable unmet market needs in the area of hypertension, ophthalmology, cardiology and diabetes. Rainbow Medical’s shareholders include Medtronic, Abbott and Sony corporations. Mr. Cohen-Arazi has over 25years of experience in the medtech and biotech industries where he held executive management responsibility in both operations and business management. Prior to establishing Rainbow Medical, Mr. Cohen-Arazi served as Co-Founder & CEO of IntecPharma, Israel, a company specializing in drug development and delivery and as Chairman of CollPlant Ltd., a both public companies traded in Tel-Aviv stock exchange. Previously, Mr. Cohen-Arazi was GM & V.P., Site Head at California based Amgen Corporation, where he established and led several global strategic initiatives and partnerships to develop and manufacture blockbuster biopharmaceuticals. Prior to Amgen, Mr. Cohen-Arazi was Senior VP at Immunex Corporation in Washington and before that VP and General Manager at the Merck-Serono Group in Switzerland and Israel. Mr. Cohen-Arazi holds advanced degrees in Agriculture and Microbiology from the Hebrew University of Jerusalem
Lori Chmura, CEO – Dune Medical
Lori is a seasoned veteran in the healthcare space beginning her career as a CCRN working in critical care, trauma and emergency medicine at Yale New Haven Hospital, Emory University Hospital and St Joseph’s of Atlanta. She transitioned into the medical device industry as a Clinical Specialist with Datascope, now Maquet and with a track record of success took on increasing levels of leadership completing her 10 year tenure as the Vice President of North American Sales. She spent time as a regional CorporateSales Director for Medtronic and then moved over to Covidien Endo mechanical where she spent 4 years as the VP of Sales and Marketing. Most recently she served as the VP of the US for Cordis, a Johnson and Johnson company. Lori is known as a champion of change management and passionate about delivering growth. She has led numerous Women’s leadership imperatives and currently serves as the Presidenton the Atlanta Chapter board for the Healthcare Business women’s Association in addition to being on the board of directors for the Pine Crest Academy in Atlanta. Lori earned a BSN from Southern Connecticut State University.
Yossi Gross, Founder & CEO – Rainbow Medical
Mr. Gross is a medical device industry visionary, and one of its most experienced and successful entrepreneurs. Mr. Gross is a founding partner of Rainbow Medical. Mr. Gross first started his professional career as a project manager of the Lavi (IAI Lavi) program for the Israel Air Force. Since then, Mr. Gross has founded and co-founded over 27 medical device companies providing innovative solutions to significant unmet medical needs. He is the owner of more than 700 patent and patent applications. Mr. Gross holds an MSc degree in aeronautical engineering from the Technion Israel Institute of Technology in Haifa, Israel.
Gary Grinspan, CEO – Future Crops
Sagi Brink-Danan, CEO & Board of Directors - HIL Applied Medical Ltd.
Sagi Brink-Danan, MSc, MBA – Chief Executive Officer, Board Director Sagi brings over 17 years of entrepreneurial and executive medical-device experience, mostly in the US, building and growing companies in pain monitoring, orthopedics, robotic spine surgery, advanced wound healing and urology. At Mazor Robotics (NASDAQ: MZOR; recently sold to Medtronic for $1.6B) he was hired as the second employee in the US, rose quickly through the ranks to senior management positions, and helped develop and lead the company’s nation-wide presence and operations. Sagi was also the founding CEO of Perfuzia Medical, where he took the company from inception through seed and A-round financing, product development, IP development, clinical studies and strategic partnerships. In his position as VP at SRS Medical Sagi led the international commercialization of an advanced urological technology, developed at an investment of over $100M. Prior to his medical-device career Sagi served in an elite a Navy unit of the IDF (Israel Defense Forces), where he attained the rank of Captain. He holds an MBA Cum-Laude from Babson College (Boston, MA, USA) in entrepreneurship and international business, and an MSc in Biomedical Engineering from Tel Aviv University (Israel) with a full merit scholarship; his Master’s thesis was spun out as a startup company funded by Israel’s Office of the Chief Scientist. Sagi also holds a BSc in Electrical and Electronics Engineering from TAU (dean’s list, merit scholarship), and is a graduate of Israel’s Naval Officer Academy in Haifa. He has several scientific and medical publications, and holds numerous patents worldwide.
Ronen Raz, CEO – MinInvasive Ltd.
Former Director of Engineering at Comverse (NASDAQ: CMVT), VP Operations at superDimension (acquired by COVIDIEN), and Chief Operating Officer at VGEN.
Ariel Beery, CEO – MobileODT
Ariel Beery is co-founder and Chief Executive Officer of MobileODT, a company transforming healthcare by offering a family of smart, AI-powered internet-connected medical devices that health care providers can use at the point-of-care for a variety of examinations. Our leading product is the Enhanced Visual Assessment (EVA) System for colposcopy, used for women's health services in 26 countries around the world (and 31 States in the US). Prior to MobileODT, Ariel served as the Global CEO of the PresenTense Group, an accelerator for social ventures he co-founded in 2005 that has launched over 1000 startups. Ariel has a B.A in Economics and Political Science from Columbia University, a MPA (Masters in Public Administration) from New York University (NYU) in Management, and an MA from NYU in Jewish Studies.
Jason Rudd, CMO - Neteera
Mr.Rudd brings over 20 years of industrial and automotive high-tech sales experience to Neteera, most recently having spent 11 years as Senior Director of OEM and Tier1 sales at Mobileye (NYSE: MBLY). Prior to this Mr.Rudd was the Global Sales Champion for Advanced Driver Assistance Systems during his 10 year tenure at TRW Automotive (previously Lucas Varity).
Liron Fendell, CEO – Nutritional Growth Solutions
Liron is an executive and corporate attorney with proven experience in managing growth, producing healthcare innovations, and executing complex deals.She is passionate about nutrition and loves creating clean, clinically tested nutrition solutions for children.Liron joined NGS in 2014 and led it to extraordinary growth and achievements. Liron has an L.L.B and an MBA from Tel Aviv University.
Anne Rogove, Senior Associate – Gurnet Point Capital
Annie Rogove is a Senior Associate at Gurnet Point Capital, a healthcare investment fund based in Cambridge, MA that invests across all stages of product development through to commercialization with a hybrid venture and private equity strategy encompassing life sciences and medical technologies. During her time at Gurnet Point, Annie has been an integral member of the investment team, working on public and private transactions worth over $1.5 billion across a wide range of deal structures. Prior to Gurnet Point, Annie spent over four years with L.E.K. Consulting in Boston, Sydney and New York. As a member of the firm’s Life Sciences and Med Tech practice, Annie advised clients ranging from startups to the world’s largest pharmaceutical companies on M&A, portfolio prioritizations, and strategic initiatives.
Zeev Zehavi,VP Venture Investments - Johnson & Johnson Development Corporation
Zeev Zehavi is Vice President of Venture Investments for Johnson & Johnson Innovation - JJDC, Inc. (JJDC) and joined in 1999. He is based out of offices in Israel and Belgium. Mr. Zehavi’s background covers an extensive array of health care and related businesses. He spent over 10 years with Teva Pharmaceutical Industries, Ltd., including a five-year assignment as President of the bulk chemical business in North America. He returned to Israel as President of Clal Pharmaceutical Industries (CPI) for four years before starting his own consulting business, Pharma Zee, Ltd. While operating this consultant business for medical device and pharmaceutical start-up companies, Mr. Zehavi initiated contacts with various Johnson & Johnson companies.
Mr. Zehavi holds a Bachelor of Science from Hebrew University of Jerusalem and a Master of Business Administration in Marketing and Finance from Tel Aviv University. He is fluent in Hebrew, English, and Arabic.
Dr. Nissim Darvish, Senior Managing Director – Orbimed Advisors Israel
Nissim is a veteran of the lifescience industry, with 15 years of experience covering medical technology development, corporate leadership and investment management. Nissim spent eight years with Pitango, where he was a General Partner managing life sciences investments. Previously, Nissim was the founder and CEO of Impulse Dynamics, which he led for six years, culminating in a $250 million realization event. Nissim obtained his M.D. and Ph.D. in Biophysics and Physiology from the Technion in Israel, and subsequently conducted his postdoctoral research at the NIH. He has published over 100 patents, authored over 20 publications and received eight prizes and awards.
Oded Har-Even, Partner & Managing Director – Zag S&W International Law Firm
Oded is the Managing Director of ZAG-S&W USA. Oded’s practice focuses of capital markets, specializing in advising public companies on financing and ongoing corporate governance, disclosure and compliance matters. He has been involved in numerous public offerings and exchange listing in Wall Street of both private and TASE-listed Israeli companies. He also represents extensive experience representing New York investment banks in public offerings and private placements. Oded also represents U.S. funds in their investments into Israeli companies.
Jacob BenArie, CEO - Q2Pharma
15+ years of experience as a CEO and entrepreneur in life science start–up companies. Prior to establishing Q2Pharma, Jacob served as the CEO of Orgenesis (NASDAQ:ORGS) a cell therapy company aimed to cure diabetes by transdifferentiating liver cells into autologous insulin producing cells. Jacob established Orgenesis activities in Israel, USA and Belgium. Previously served as a co-founder and CEO of Beta-Stim Ltd. a privately held Israeli company backed by Boston Scientific, aimed to develop a treatment for obese type 2 diabetics. Jacob also co-founded Slender Medical Ltd, an ultrasound based product for removal of cellulitis and body contouring. Jacob is also a co-founder of Jaz Medical Ltd, a private held boutique investment house dedicated to pre seed medical devices and also co-founded the MDDMI conference in Israel
Dr. Opher Shapira, CEO – Nucleix Ltd.
Opher is an experienced entrepreneur and manager with close to 20 years of experience in the medical industry. Opher was the founder, President and CEO ofBioViewLtd. (Public TASE).Opher has a PhD in Physics from Yale University and a B.Sc. in Physics and Computer Sciences from Tel Aviv University.
Ariel Weinstein, CEO - OCON Healthcare
In the healthcare business since 1996, Mr. Weinstein who holds a BSc in Emergency Medicine and a MSc in Management, has been involved in clinical roles in the cardiology and orthopaedic industries and in executive roles since 2006.
Jordan Rubinson, CEO - Regenera Pharma
Mr. Rubinson has worked for more than 25 years in the pharmaceutical industry with large pharma companies like Pfizer, GlaxoSmithKline, and Aventis.
He is currently the CEO of Regenera Pharma, an Israeli biotech company with a drug targeting diseases of the Central Nervous System. The company’s lead drug candidate is being studied in a phase 3 clinical trial for stroke of the optic nerve and a phase 2 clinical study in Canada for mild/moderate Alzheimers.
Mr. Rubinson worked previously in early stage companies as chief commercial officer for Champions Oncology, where he grew sales 30% annually to $20M and brought the company to profitability. Just prior, Mr. Rubinson was the CEO of Polyheal Ltd, which was sold to TEVA at a $90M valuation.
While in pharma, Mr. Rubinson worked at Pfizer as the marketing director for Israel. At GSK in U.S. marketing, he managed assets of over $300M in annual sales, brought to market several category-leading vaccines, and earned the company’s Frost and Sullivan Market Engineering Excellence Award.
He also worked at GSK France, managing a large field force division of over 100 employees. While at Aventis, Mr. Rubinson had assignments in France, Canada and the U.S. Mr. Rubinson holds an engineering degree from Columbia University and an MBA from MIT’s Sloan School of Management.
Dr. Amotz Shemi, CEO – Silenseed
Dr. Shemi is Silenseed’s co-founder and has served as the company’s Chairman of the Board of Directors and Chief Executive Officer since incorporation in 2008. Prior to founding Silenseed, from 2005 to 2008, Dr. Shemi served as the Senior Vice President Technologies at Medinol Ltd., a world leader in design, development and manufacturing of stent and stent delivery systems. Prior to that time, Dr. Shemi was the chief executive officer of several private Israeli technology companies, including Color-Chip Ltd (acquired by Sanan Optoelectronics Co. Ltd. for $300mm). Dr. Shemi holds a Ph.D. degree in Physics from the Tel Aviv University. He is a single author and co-author of many scientific papers and a single inventor and co-inventor of more than a dozen of patents.
Yossi Abu, CEO - TechsoMed
Yossi is the CEO & Founder of TechsoMed, an Israel-based medical device company, developing real-time monitoring systems for ablation procedures.
Experienced Chief Executive Officer with extensive experience in the medical device industry, skilled in sales, management, product marketing, start-ups, and leadership. A strong business development and business strategy professional with a Master of Science (M.Sc.) focused in Mechanical Engineering from Technion - Israel Institute of Technology.
Shuki Porath, CEO – Valcare Medical
Mr. Shuki Porath has over 20 years of medical device managerial experience, bringing products from concept to market. Prior to joining Valcare Medical, Mr. Porath served as President & CEO at Keystone Heart.Formerly, Mr. Porath served as Senior Executive at Biosense Webster, a Johnson & Johnson Company, holdingvarious executive positions in the areas of product management, business development and clinical applications. He holds a B.Sc in Electrical Engineering, an M.Sc. and an MBA –all from the Technion, Israel Institute of Technology
Tal Gollan, Founder & CEO - Virility Medical
Tal Gollan is the Founder and CEO of Verility Medical. He is also the Co-founder of Trisol Medical. Tal has 13 years of experience in medical device startups. He has a B.Sc. in Biomedical Engineering.
Jacob Keidar, Ambassador of the State of Israel to Switzerland and Liechtenstein
Ambassador Keidar is a veteran of the Foreign Service, having been born in 1956 and working for the Ministry for more than 35 years.
After graduating from the Hebrew University (BA in International Relations and East Asian Studies and MA in International Relations), his first and second postings as a young diplomat led him to Tokyo.
His posting was as Consul general in Shanghai (1997-2001). He was fortunate to witness the rapid development of China in the 90s and was able to provide a helping hand to Israeli companies that would eventually establish businesses there.
During the next six years (2001-2007), he served as the Director of the Multilateral Peace Talks Coordination Department (part of the time as Acting Deputy Director General for Middle Eastern Affairs 2005-2007).
As the Ambassador to Kenya (2007-2011), accredited to Uganda, Seychelles, Tanzania, Malawi and Zambia, Ambassador Keidar got to enhance the friendly relations between Israel and many African countries. At the same time, the Ambassador was the representative to UNHABITAT and UNEP. It was a privilege for him to contribute to the professional agenda of those UN organizations and to assist in promoting the SDG's.
Upon his return, he was posted as Inspector General of the Foreign Service (2011-2016).
Currently, he serves as the Ambassador to Switzerland and Liechtenstein. In this position, his special focus is to enhance relations in the fields of economy, trade, science, innovation, culture and politics and he is looking forward to celebrating 70 years of diplomatic relations Between Switzerland and Israel this year.